Tirzepatide Helps Patients With OSA and Obesity Achieve OSA Remission
Tirzepatide treatment may lead to OSA remission or mild nonsymptomatic OSA in patients with moderate to severe OSA and obesity.
These findings were reported at the American College of Chest Physicians (CHEST) 2025 Annual Meeting, held October 19 to 22, in Chicago.
Investigators compared OSA improvement rates among patients with obesity treated with tirzepatide vs placebo, conducting post-hoc analyses of 2 phase 3 randomized, double-blind studies.
- The researchers assessed the efficacy and safety of tirzepatide in adults with moderate to severe OSA and obesity.
- Patients were randomly assigned 1:1 to once-weekly tirzepatide or placebo for 52 weeks.
No direct quote available in the text.
Author's resume: Tirzepatide aids OSA remission.
More News
- Swim and Dive Fall 2025 Newsletter
- Bitcoin Price Might Never Fall Below $100,000 Again
- First Duel Night Abyss Figure Is Based on Psyche
- Tesla revives 'Mad Max' mode in Full Self-Driving - FOX 24 WTAT
- Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
- Second Phase of FIFA 2026 World Cup Tickets Launches
- Tesla driver avoids plane crash caught on video, fans falsely credit self-driving
- How Gaming Glasses Are Becoming Essential for Gamers? | NorthPennNow
- Newsom considering 2028 run, calls Trump an ‘invasive species’